Monitoring of the presence of EGFR-mutated DNA during EGFR-targeted therapy may assist in the prediction of treatment outcome.
Moiseenko FV, Volkov NM, Zhabina AS, Stepanova ML, Rysev NA, Klimenko VV, Myslik AV, Artemieva EV, Egorenkov VV, Abduloeva NH, Ivantsov AO, Kuligina ES, Imyanitov EN, Moiseyenko VM.
Moiseenko FV, et al. Among authors: klimenko vv.
Cancer Treat Res Commun. 2022;31:100524. doi: 10.1016/j.ctarc.2022.100524. Epub 2022 Jan 31.
Cancer Treat Res Commun. 2022.
PMID: 35101831
Free article.
Clinical Trial.